12,100 Shares in Twist Bioscience Co. (NASDAQ:TWST) Bought by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS bought a new position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 12,100 shares of the company's stock, valued at approximately $562,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TWST. Thrivent Financial for Lutherans increased its position in Twist Bioscience by 54.6% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after buying an additional 532,040 shares in the last quarter. State Street Corp grew its stake in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after acquiring an additional 526,028 shares during the period. Wellington Management Group LLP raised its position in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Jennison Associates LLC lifted its holdings in shares of Twist Bioscience by 80.2% in the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after purchasing an additional 302,884 shares in the last quarter. Finally, American Century Companies Inc. grew its position in Twist Bioscience by 63.5% in the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company's stock valued at $35,148,000 after purchasing an additional 293,751 shares during the period.

Twist Bioscience Price Performance

Shares of TWST traded up $0.80 during mid-day trading on Monday, reaching $36.99. 2,150,078 shares of the stock traded hands, compared to its average volume of 961,846. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -10.94 and a beta of 2.34. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The firm has a fifty day moving average price of $43.49 and a 200 day moving average price of $44.99. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analysts' expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company's revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.75) EPS. As a group, equities research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $39,776.10. Following the transaction, the insider now directly owns 112,221 shares of the company's stock, valued at $5,538,106.35. The trade was a 0.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Laponis sold 5,886 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the transaction, the chief financial officer now owns 110,096 shares in the company, valued at $4,762,752.96. This represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,682 shares of company stock worth $1,582,011. 3.01% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TWST. Wolfe Research started coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th. Barclays set a $58.00 price target on Twist Bioscience and gave the company an "overweight" rating in a research report on Monday, February 3rd. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Robert W. Baird increased their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Twist Bioscience has an average rating of "Moderate Buy" and an average target price of $54.10.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.